10 Antitrust Developments And Trends to Watch in 2018
Trump’s agency appointments are setting the antitrust agenda in 2018. Cooley lawyers offer insights on what to expect in the new year, including:
- An increased scrutiny on vertical mergers
- A heightened focus on structural remedies in enforcement actions
- A continued spotlight on the pharmaceutical industry, particularly with respect to proposed mergers and reverse payment agreements
- A potential Supreme Court ruling on the rule of reason
- Criminal prosecutions of no-poach and wage-fixing agreements
- Increased enforcement of cartel activity
- An emphasis of IP owners’ rights in antitrust actions
- A focus on sham litigation and the misuse of administrative processes to delay generic drug entry
- Heightened attention to the use of algorithmic pricing software in the US and EU
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.